to the Rous sarcoma virus (RSV) integrase catalytic core. As the substituents on the quinoline moiety are the same as on salicylic acid, the energies of hydroxy benzoic acid tautomers were also computed both in vacuo and embedded in a continuous medium which had the dielectric constant of bulk water, using the recent CPCM technique. The CPCM method was then applied to the two integrase inhibitors to estimate the tautomer population in water. The binding site of the compounds on the RSV integrase catalytic core was determined through a docking protocol, consisting of coupling a grid search method with full energy minimization. The designed method is a way leading to identification of potent integrase inhibitors using in silico experiments.
AIDS is essentially a viral disease and should be treated by antiretroviral agents (Ho et al., 1995) . The advent of combination antiretroviral therapy has made it possible to suppress the replication of HIV-1 in infected persons to such an extent that the virus becomes undetectable in the plasma for more than two years, but seems to persist in peripheral-blood mononuclear cells. This means that HIV-1 infection can be controlled but not eradicated by current treatments (Zhang et al., 1999; Furtado et al., 1999) . It is therefore important to search for agents that could block the virus at these steps of its replicative cycle, which are not affected by current treatments. From this standpoint, HIV DNA integration into the genomic DNA of host cells, a crucial step in the replicative life cycle of the virus, constitutes a particularly attractive target for AIDS chemotherapy drugs, including potential synergy with currently available HIV reverse transcriptase and protease inhibitors (De Clercq, 1995; Pommier & Neamati, 1999) . In HIV-1 and other retroviruses such as RSV, integration is mediated by a viral enzyme, integrase, which is necessary for the production of progeny viruses (LaFemina et al., 1992) . The integration function is composed of two steps both consisting of the nucleophilic attack of a phosphoester bond by the lone pair of a hydroxyl group (Engelman et al., 1991) . In the first step, called 3¢ processing, the enzyme catalyzes the hydrolysis of a phosphoester bond, which removes two nucleotides from either of viral DNA strands and forms free 3¢-OH groups at a conserved CA dinucleotide sequence. In the second step, called strand transfer, these groups are used as nucleophilic agents and attack phosphoester bonds in opposite strands of the genomic DNA separated by five base pairs in HIV-1 and four base pairs in RSV (reviews: Brown, 1990 ; Katz & Skalka, 1994) .
The HIV-1 integrase produced in an Escherichia coli expression system, can carry out both 3¢ processing and strand transfer in vitro in the presence of divalent cations such as Mg ++ and Mn ++ (Bushman & Craigie, 1991) . It can also, in the same ionic environment, carry out the apparent reversal of the transfer step in the presence of a synthetic Y-shaped oligonucleotide (Chow et al., 1992) . Not the entire protein, but only its catalytic core, IN(50-212), containing the residues 50 to 212, is required for the disintegration step, showing that the core contains the enzyme active site. Site-directed mutagenesis experiments showed that catalytic activity is abolished by the substitution of any of the three absolutely conserved carboxylate residues, two aspartic residues D64, D116 and a glutamic residue E152 (the so-called D,D-35E motif). The same arrangement of catalytically essential carboxylates is conserved not only in all retroviral integrases but also in enzymes that catalyze cognate reactions such as prokaryotic transposases. This observation strongly suggested that their spatial conformation should be similar to the conformation of the corresponding amino acids D64, D121 and E157 in the RSV integrase catalytic core. Although this seemed to be disproved by the first crystal structures of the HIV-1 catalytic core (Dyda et al., 1994) , it was finally confirmed by two independent groups (Maignan et al., 1998; Goldgur et al., 1998) . The dication is in the immediate vicin-ity of the essential carboxylates, which is a common feature among enzymes in nucleic acid biochemistry (Cowan, 1998 each atom is fitted to reproduce the solvation energies at a computational level (HartreeFock with a medium size basis set) allowing the study of relatively large systems (Barone et al., 1997) . This approach should yield an estimate of the availability of the various tautomers in water. Moreover, it is possible to classify the inhibitory power by docking the drugs to the RSV integrase catalytic core.
MATERIALS AND METHODS

Chemicals.
The chemical formulae are shown in Fig. 1 . Their syntheses have been described by Zouhiri et al. (2000) . Drug 1 was an orange-red powder of sodium carboxylate: R7 = CO 2 Na, R8 = OH, R3¢ = OCH 3 and R4¢ = OH. Drug 2 was a yellowish powder: R7 = CO 2 H, R8 = OH, R3¢= OH and R4¢ = OCH3 that, in contrast to the former compound, was difficult to dissolve in Tris buffer. Spectra were measured on an Uvikon 941.
Modelling of protein structure. Before making any docking attempt, it was necessary to know the conformation of the catalytic core. First, the structure of the catalytic core of RSV integrase published by Bujacz et al. (1995) was minimized with our minimizer (Le Bret et al., 1991) and the AMBER force field (Cornell et al., 1995) to remove any close contact. The missing atoms in the crystallographic coordinate file were set using the XRAY option in the EDIT module of AMBER. The total coulombic charge of the catalytic core (with the divalent bication) was +10 proton charges. The effect of the minimization on the RSV integrase catalytic core is very small. Docking algorithm. The docking method that was used in this study has been incorporated into our program MORCAD (Le Bret et al., 1991) . It consists of several steps: a grid search fit by rotating (15°increments) and translating (0.916 Å increment) the drug while holding the protein rigid as described by Katchalski-Katzir et al. (1992) . A score function that takes into account the surface overlap and the electrostatic interaction (Rogers & Sternberg, 1984; Gabb et al., 1997 ) is computed. The 1100 best conformations are minimized using a quasi newtonian algorithm (Le Bret et al., 1991) to allow some flexibility. The force field is the AMBER forcefield (Cornell et al., 1995) for amino acids, the Aqvist (1990) parameters for the Mg ++ divalent cation and a sigmoidal dielectric constant to mimic the aqueous medium (Lavery et al., 1986) . The parameters for the drugs were taken from those of the unmethylated compounds (Ouali et al., 2000) . A 10 Å cut-off was used in the nonbonded interactions during minimization. Once minimization of the whole system (protein + drug) was completed, the interaction energy was re-evaluated without the cut-off. The drug-catalytic core interaction energy is the sum of all interactions between any drug atom and any catalytic core atom. Such grid searches have the advantage of getting to the neighborhood of the correct solution (Shoichet, 1996) . The full cycle requires 24 h of SGI R10000 195 Mhz processor time per tautomer. Quantum mechanical calculations. The structure of the drugs was optimized through the ab initio program GAUSSIAN98 (Frisch et al., 1998) in each tautomer and each rotamer for use in the docking procedure. The Gibbs free energy difference was computed at 298.27 K using the Freq option of GAUSSIAN98.
RESULTS
Spectroscopic properties
The absorption spectrum of drug 1 is shown in Fig. 2 . Drug 1 is weakly fluorescent in 0.1 M Tris buffer. This is not a homogeneous solution since the emission spectrum depends on the excitation wavelength. For instance, there is no detectable fluorescence when drug 1 is excited at 550 nm but a very weak fluorescence can be measured when it is excited at 350 nm. When the compound is left in the aqueous buffer, its absorption spectrum varies by 10% during the first hour and becomes stabilized after a day. The kinetics is rather slow with respect to the time required to measure the IC 50 . The weak fluorescence vanishes with time. Obviously the drug becomes degraded. The degradation might be related to the degradation of stilbene: the major products in the photolysis of trans-stilbene in the near ultra violet are trans-and cis-stilbene. In the case of cis-stilbene photolysis the major products are trans-and cis-stilbene but dihydrophenanthrene also can be formed (Waldeck, 1991) . No fluorescence of drug 2 could be detected when it was directly dissolved in Tris buffer. Because of its low solubility, the drug was first dissolved in dimethylsulfoxide, then in Tris buffer. In contrast to drug 1, no degradation of drug 2 was observed after it had stayed for 24 h in 0. quench the fluorescence and modify the absorption spectrum in a way that is comparable to the effect of aging.
CPCM calculations on hydroxy benzoic acids
In our styrylquinoline derivatives, the carboxy and hydroxy substituents lie at adjacent positions R7 and R8, exactly as in salicylic acid. It has long been known that in salicylic acid, the neighborhood of hydroxyl and carboxyl substituents favors the formation of a chelate ring, in which a divalent hydrogen atom is a link (Branch & Yabroff, 1934) . Hence, both pKs of salicylic acid significantly differ from those of meta and para hydroxy benzoic acids (Dunn & McDonald, 1969; Lange, 1967) . It is generally accepted that the enol form of salicylic acid prevails both in ground and excited states (Lahmani & Vol. 47 Retroviral integrase inhibitors 15 Zehnacker-Rentien, 1997; Sobolewski & Domcke, 1998). It was interesting to estimate the validity of this model in our styrylquinoline derivatives (see Fig. 1 ) and compute the energy and the free energies both in vacuo and in water in a case where the pKs are experimentally known. If the computations were correct, the experimental pKs of the two compounds should follow the expression: DpK = DG/RT log 10 where RT is the Boltzmann factor, and DG is the free energy difference of the protonated and unprotonated forms of a compound. To predict a pK with an error of 1, we should have an error in the energy computations less than 1.4 kcal/M. Such an accuracy is still a challenge for the to-day state of art and we would be very satisfied if we could sort out the conformers and tautomers.
If we exclude the case in which both carboxylic oxygens are protonated, the ortho and meta hydroxy benzoic acids have 15 forms: 8 neutral forms, 6 with a charge of -1 and one with a charge of -2 (cf. Fig. 3 ). Because of its symmetry, the para compound has only 8 forms. Table 1 shows the results. From the in vacuo Hartree-Fock results, the ortho keto 00. form is predicted to be more favorable than the enol form .0 which is not realized experimentally in aqueous solution. When electron correlation is more accurately treated with B3LYP/6-311G(2d,p), the keto form is still more favorable than the enol form by 1.3 kcal/M (result not shown in Table 1 ). When solvent effects are included with CPCM, the enol form .0 gets more favorable than the keto form 00. (see Table 1 ). Moreover, at this level, the meta compound is more acidic than the ortho compound, in contrast to experimental data. We conclude that CPCM does not give good results when it is used with B3LYP. When CPCM is used at the HF/ 6-31+G(d) level, the DG correlates poorly with the experimental pKs, but the ordering is correct and this is a significant improvement. Finally, we note that the DG = 264.9 kcal/M for water protonation is probably underevaluated. It should be greater than 277.2 kcal/M if all hydroxybenzoic acids have a charge of -1 when dissolved in water and less than half of 564.9 kcal/M (282.4 kcal/M) to prevent them from having a charge of -2. Tables 2 and 3 show the results concerning drugs 1 and 2, respectively. The keto forms are favored in vacuo, but the enol forms prevail in the CPCM computations.
Calculations on the styrylquinoline derivatives
The docking results (Tables 2 and 3 ) may be summarized as follows : u both drugs bind closely to the Mg ++ divalent cation that is embedded in the crystallographic structure in the immediate vicinity of the D,D-35E motif. This remains valid whatever the tautomer or rotamer form. The atoms of the drug that are close to the cation are indicated in the Tables. In most cases, the drugs bind by the quinoline moiety. The keto form is favored. The conformations are coded by two binary numbers separated by a dot. If the substituent is not protonated the number is replaced by a blank. The first number concerns CO 2 H. The low bit of the first number is set to 1 if the oxygen that carries the proton is close to the hydroxyl group and is set to 0 otherwise. The high bit is set to 1 if the proton is close to the cycle. The second number concerns the hydroxyl group. A keto form is noted by a blank. If the proton points to the carboxyl group the bit is set to 0.
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Conformation
In vacuo
In water (CPCM) CO 2 dihedral (degrees) The rotamer conformations are encoded as described in Fig. 2 . In vacuo DEs, are the optimised ab initio RHF /6-31G(d) energies. In vacuo DGs contain the thermal correction to the Gibbs energy multiplied by the ad hoc factor 0.9. The CPCM DGs contain the latter thermal correction and the optimised CPCM total free energy (with non electrostatic terms) computed at either HF/6-31+G(d) or B3LYP/6-311G(2d,p) level in a medium of dielectric constant equal to 78.39. The last line reports the deprotonation energies of H 3 O + in vacuo and in water.
u The drugs seem to bind either in a "horizontal" slit as in Fig. 4 or "vertically" as in Fig. 5 . This is shown by the characters h or v in Tables 2 and 3 . When it binds horizontally, the drug separates the two aspartic acids from the glutamic residue on the catalytic core of the D,D-35E motif and touches the following residues: D64, N122, N149, Q153, N160. In the vertical binding site the drug touches the following residues: D64, Q153, E157, N160, W176, R195 and V196. u The drug that was planar in the rigid docking phase becomes slightly distorted after minimization. The distortion is always small so that only the final values of the angle a are indicated because they are always very close to their starting values (0°or 180°). Table 3 . Energy and geometrical characteristics of various drug 2 tautomers, in vacuo, in water, and bound to the ASV integrase catalytic core.
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Rotamer coding for R7 and R8 is the same as in Fig. 2 . If R3¢ points towards R4¢ the bit is set to 0. If R4¢ points towards R3¢ the bit is set to 0. The catalytic core is shown as a wire model. The three carboxylic acids D64, D121 and E157 are in light gray. The drug is darker and hides the Mg ++ divalent cation. Here the divalent cation (black) can be seen. These results show that the drug inhibits the integrase by complexing the protein close to the active site. This binary complex is of course much simpler to model than a ternary complex in which DNA is somehow involved. Consequently, drug design should not be as difficult as could have been imagined. While this manuscript was being revised, another inhibitor 5CITEP, was found by X-ray crystallography to be bound centrally in the active site of the HIV-1 integrase catalytic core (Goldgur et al., 1999) . As this compound has two cycles connected by a linker that is similar to ours, the localization found here in silico for styrylquinolines is probably right. We found that the keto tautomer showed a better interaction energy with RSV integrase than the end tautomer. Unfortunately, it is not abundant in solution. In the near future we should be able to design drugs that have the right tautomeric form.
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